Myasthenia Gravis (MG)
Home / Myasthenia Gravis (MG)
Myasthenia Gravis (MG)
Myasthenia Gravis (MG) is caused by autoantibodies targeting the neuromuscular junction, leading to fatigable muscle weakness. New targeted therapies include:
- Efgartigimod (Vyvgart®) – neonatal Fc receptor (FcRn) blockade
- Ravulizumab (Ultomiris®) – complement inhibition
- Rozanolixizumab (Rystiggo®) – subcutaneous FcRn inhibitor
These therapies allow for rapid symptom control while minimizing long-term immunosuppression.
Your Financial Contribution Can Help Us Fund Critical Programs & Initiatives
As a Nonprofit organization, we are deeply committed to raising awareness, providing patient support, and advocating for research for individuals living with various disease states.
Quick Links
Rare Diseases
Contact Us
For general questions about our organization, our mission, or how you can get involved, please email us. We endeavor to respond to all inquiries